The study, whose findings are summarized under the title describing how HDAC1 maintains metabolic homeostasis in nucleus pulposus cells via post-translational modification interactions with YBX1, adds a significant piece to the puzzle of intervertebral disc degeneration, a condition that affects a large proportion of the adult population and is a leading contributor to chronic low back pain. By identifying a molecular axis that links chromatin-modifying enzymes to metabolic regulation, the work suggests that disc degeneration may be driven not only by mechanical loading and aging but also by specific, potentially targetable, biochemical failure points inside the cells themselves.

To appreciate why this matters, it helps to understand the harsh environment in which nucleus pulposus cells operate. The disc interior is poorly supplied with blood vessels, meaning nutrients such as glucose and oxygen arrive only by diffusion through surrounding tissue, while metabolic waste products such as lactate accumulate locally. Cells in this avascular niche must survive on comparatively little energy while simultaneously producing and maintaining an abundant extracellular matrix rich in proteoglycans and collagen, which gives the disc its ability to absorb compressive forces. When the metabolic balance tips — whether through nutrient deprivation, oxidative stress, or the cumulative damage of aging — the cells shift toward catabolic behavior, producing matrix-degrading enzymes and inflammatory mediators that accelerate tissue breakdown.

HDAC1 belongs to a family of enzymes that remove acetyl groups from histone proteins, the spools around which DNA is wound. By deacetylating histones, HDAC1 generally compacts chromatin and represses gene expression, but the enzyme also acts on many non-histone proteins, influencing their stability, activity, and interactions. This dual capacity makes HDAC1 a candidate regulator of programs that must respond quickly to cellular stress, including the metabolic adaptations that nucleus pulposus cells require to survive their nutrient-poor surroundings. Previous work across multiple tissues has implicated HDAC enzymes in cell survival, differentiation, and inflammatory signaling, but their specific role in disc cells has remained incompletely defined.

The new study centers on the interaction between HDAC1 and YBX1, a so-called cold-shock protein that functions as both a DNA- and RNA-binding factor and as a coordinator of stress responses. YBX1 has been linked to cell proliferation, survival under stress, and the regulation of metabolic gene expression in several biological systems. Crucially, both HDAC1 and YBX1 are subject to post-translational modifications — chemical tags such as acetylation, phosphorylation, ubiquitination, and others that are appended to proteins after translation and that can dramatically alter protein behavior. The researchers report that the functional relationship between HDAC1 and YBX1 is governed by such modifications, meaning that the enzymes and tagging systems that install or remove these marks effectively control how the two proteins work together.

According to the findings, when this HDAC1–YBX1 axis is intact, nucleus pulposus cells maintain metabolic homeostasis: their energy-generating pathways remain balanced, their matrix-producing functions are preserved, and degenerative signaling is held in check. When HDAC1 activity or its interaction with YBX1 is disrupted, the cells lose this equilibrium. The consequence, as described in the study, is a drift toward metabolic dysfunction of the kind observed in degenerated disc tissue, providing a mechanistic explanation for how epigenetic changes can translate into the structural failure of the disc over time.

The emphasis on post-translational modification crosstalk is perhaps the most technically significant aspect of the work. Post-translational modifications rarely act in isolation; a single protein may carry multiple marks that compete or cooperate with one another, and enzymes that install one mark can influence the deposition or removal of another. In the case of HDAC1 and YBX1, the study indicates that the acetylation state of the proteins shapes their physical interaction and, by extension, the downstream metabolic programs they regulate. This kind of modification crosstalk provides a rapid, reversible layer of control that operates alongside transcriptional regulation, allowing cells to adjust metabolism on short timescales in response to stress.

For the field of disc biology, the results help connect several previously parallel strands of research. Investigators have long documented that degenerated discs show altered gene expression, mitochondrial dysfunction, increased oxidative stress, and shifts in glucose and lactate metabolism. Separately, epigenetic studies have catalogued changes in histone modifications and DNA methylation in disc disease. By showing that a chromatin-associated enzyme directly maintains metabolic homeostasis through a modification-dependent interaction with a stress-response protein, the new work provides a causal bridge between these observations: epigenetic regulation is not merely a readout of degeneration but an active participant in keeping disc cells metabolically fit.

The translational implications are cautiously encouraging. If the HDAC1–YBX1 axis can be measured or modulated, it could inform strategies aimed at slowing or preventing disc degeneration, from biomarkers that identify early metabolic failure in disc cells to therapies designed to restore the interaction or its downstream protective programs. However, the study also underscores a central challenge in targeting epigenetic enzymes: HDAC1 performs essential functions in many cell types throughout the body, so any therapeutic approach would need to achieve specificity for the disc environment or exploit the modification crosstalk in a way that spares other tissues. The authors’ mechanistic framework offers a starting point for designing such selective interventions, but considerable preclinical work would be required before any clinical application.

Beyond the disc, the findings speak to a broader principle in cell biology: the insulation of tissue-specific metabolism by epigenetic machinery operating through networks of post-translational modifications. Cells in harsh niches — cartilage, the lens of the eye, the avascular regions of tumors — face analogous metabolic constraints, and similar enzyme-partner axes may govern their resilience. As the tools for mapping protein modifications become more powerful, studies of this kind are likely to reveal additional examples in which a single deacetylase, acting through a modification-dependent partnership, secures the metabolic foundations of long-lived cells. For the millions of people whose lives are affected by degenerative disc disease, the demonstration that HDAC1 and YBX1 jointly safeguard the metabolic health of the disc’s core cells represents a meaningful step toward understanding — and eventually intervening in — one of the most common forms of chronic musculoskeletal deterioration.

Subject of Research: The role of HDAC1 and YBX1 post-translational modification interactions in maintaining metabolic homeostasis of nucleus pulposus cells

Article Title: HDAC1 maintains metabolic homeostasis in nucleus pulposus cells via post-translational modification interactions with YBX1

Article References: HDAC1 maintains metabolic homeostasis in nucleus pulposus cells via post-translational modification interactions with YBX1. (n.d.). https://doi.org/10.1038/s12276-026-01843-8

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01843-8

Keywords: HDAC1, YBX1, nucleus pulposus cells, intervertebral disc degeneration, metabolic homeostasis, post-translational modification, epigenetics, histone deacetylase, low back pain, disc biology, chromatin regulation, Experimental & Molecular Medicine

The technique, developed by Iwona Nowak, Ahsan H. Polash, Hang T. Huynh, Mahekdeep Kaur and colleagues in the laboratories of Aishe A. Sarshad, Markus Hafner, and Daniel Benhalevy, fuses two powerful approaches that had never been married at this scale. The first is APEX2-based proximity labeling, an enzymatic tagging system that marks proteins and nucleic acids within a narrow radius of a genetically targeted protein. The second is 4-thiouridine-enhanced ultraviolet crosslinking, which covalently locks RNA-binding proteins onto their RNA targets and allows precise identification of crosslinked nucleotides. By combining these with sequential affinity purifications, first for the RNA-binding protein of interest and then for the biotin tag, the researchers built a pipeline that isolates only those protein-RNA contacts that occurred in the marked compartment.

The logic of the method is elegant in its layering. A protein of interest, such as the RNA-binding factor being studied, is expressed as a fusion with APEX2, a peroxidase that in the presence of biotin-phenol and hydrogen peroxide converts nearby molecules into biotin-tagged derivatives. Cells are first treated with 4-thiouridine, which is incorporated into newly synthesized RNA and dramatically strengthens ultraviolet-induced crosslinking between RNA and any protein touching it, a strategy borrowed from fPAR-CLIP protocols. When ultraviolet light fires, RNA-binding proteins are frozen onto their targets with nucleotide precision. APEX2 then labels everything in its immediate vicinity with biotin, creating a spatial signature.

What follows is a double selection. The researchers purify the RNA-binding protein and its crosslinked RNA fragments through an initial affinity step, recovering crosslinked RNA with mutations that reveal the exact binding sites, the hallmark of enhanced crosslinking-and-immunoprecipitation approaches. They then recover only those complexes that also carry the APEX2-deposited biotin tag in a second purification. A transcript must pass both filters to be counted: it must have been physically touched by the protein and must have been within the proximity-labeling radius, effectively bracketing the interaction in space and time. The result is a map of protein-RNA contacts that is simultaneously compartment-specific and nucleotide-resolved.

Control experiments were central to validating the approach. The team confirmed that APEX2 fusion proteins localized correctly to their intended compartments and that proximity-dependent biotinylation was restricted to the expected neighborhoods, presenting this evidence across multiple supplementary figures alongside imaging and immunoblot analyses. Without accurate spatial confinement, any apparent compartment specificity could simply reflect leakage or overexpression artifacts, so establishing the fidelity of the labeling step was essential before biological conclusions could be drawn.

With the method proven, the researchers turned it loose on three of the most intensively studied RNA-binding proteins: AGO2, the central effector of the microRNA silencing machinery; YBX1, a multifunctional nucleic acid-binding protein involved in mRNA stability and translation; and ELAVL1, better known in some circles as HuR, a regulator of mRNA stability and stress responses. All three proteins are known to operate in multiple cellular compartments, making them ideal test cases for a technology designed to disentangle location-dependent behavior.

The findings were striking. Each of the three proteins displayed distinct, compartment-specific RNA-binding patterns, targeting different sets of transcripts and even different sequence contexts depending on where in the cell it was acting. Importantly, the researchers found that these spatial differences arose through canonical motif recognition: the same proteins continued to recognize their characteristic sequence motifs in each compartment, but the repertoire of available targets, and thus the functional consequences of binding, shifted dramatically with location. In other words, the proteins did not change their binding preferences so much as their access to substrates changed, partitioning the accessible RNA targets and reshaping each protein’s regulome across the cell.

This partitioning concept has broad implications. For AGO2, compartment-specific mapping opens a window onto how microRNA targeting might differ between the cytoplasm, where canonical silencing occurs, and other locales where AGO2 has been implicated in less conventional roles. For YBX1 and ELAVL1, both implicated in cancer biology and stress physiology, knowing which transcripts are bound in which compartments could clarify how these proteins execute distinct functions from seemingly identical biochemical activities. The method essentially converts a single flat binding profile into a set of spatially annotated maps, revealing that what looked like one interactome is actually several overlapping ones.

Technically, RBProximity-CLIP also demonstrates the value of the 4-thiouridine enhancement inherited from fPAR-CLIP. Enhanced crosslinking increases crosslinking efficiency and yields the characteristic signature of crosslink-induced mutations, allowing binding sites to be pinpointed to individual nucleotides. Combined with proximity tagging, this delivers a rare combination of spatial and sequence resolution in a single experiment, something neither classical CLIP nor proximity labeling alone can provide. The authors provide detailed reagent lists, including antibodies, detection reagents for imaging and immunoblotting, and oligonucleotide sequences for library preparation, alongside full-length uncropped gel and blot images, underscoring the reproducibility infrastructure that accompanies methodological advances of this kind.

The work was a genuinely international effort, jointly led from the University of Gothenburg’s Wallenberg Centre for Molecular and Translational Medicine, the RNA Molecular Biology Laboratory at the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, and Tel Aviv University, with support from the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Swedish Society for Medical Research, the National Institutes of Health Intramural Research Program, the Israel Science Foundation, and the Hellenic Foundation for Research and Innovation. Published as an open-access article in Genome Biology, the study arrives at a moment when the field is increasingly aware that spatial context is not a luxury but a fundamental dimension of gene regulation. As RBProximity-CLIP is adopted and extended, it promises to turn the cell from a featureless bag of molecules into a mapped territory, where every protein-RNA encounter has an address, and where the grammar of gene expression can finally be read with both sequence and location in view.

Subject of Research: A subcellular-resolution RNA-binding protein mapping method combining proximity labeling and enhanced crosslinking

Article Title: RBProximity-CLIP enables subcellular mapping of RNA-binding protein interactions at nucleotide resolution

Article References: Nowak, I., Polash, A. H., Huynh, H. T., Kaur, M., Lobo, V., Scutenaire, J., Fong, M., Alluhaibi, G., Anastasakis, D. G., Hafner, M., Benhalevy, D., & Sarshad, A. A. (2026). RBProximity-CLIP enables subcellular mapping of RNA-binding protein interactions at nucleotide resolution. Genome Biology. https://doi.org/10.1186/s13059-026-04278-6

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04278-6

Keywords: RNA-binding proteins, RBProximity-CLIP, proximity labeling, APEX2, CLIP-seq, AGO2, YBX1, ELAVL1, 4-thiouridine, subcellular resolution, protein-RNA interactions, Genome Biology

The study, conducted by Jing Luo, Wangjian Zha, Jinjie Yao and colleagues across several institutions in Nanjing and Xuzhou and published in the Journal of Translational Medicine, set out to answer a deceptively simple question. Long non-coding RNAs, the vast family of RNA transcripts that do not carry instructions for making proteins, number in the tens of thousands in the human genome, yet the specific roles most of them play inside cancer cells under nutrient-deprived conditions remain largely unmapped. The researchers chose to simulate the harsh conditions of the tumor microenvironment in the laboratory by reducing glucose concentrations in the culture medium, forcing lung adenocarcinoma cells to confront the same energy crisis they would face inside a patient’s body. What they found was that this stress does not merely suppress cellular activity; it activates a specific genetic program, and GIRGL sits near the top of it.

The first step in the investigation was to establish where and when GIRGL appears. Analyzing tissue samples from patients with lung adenocarcinoma, the team discovered that GIRGL was consistently upregulated in tumor tissue compared with healthy counterparts. More strikingly, the abundance of this RNA molecule correlated with measurable clinical features of the disease, including the degree of glucose uptake observed in patients using fluorodeoxyglucose positron emission tomography, a scanning technique that highlights the most metabolically ravenous regions of a tumor. Patients whose tumors expressed high levels of GIRGL tended to have poorer overall survival in univariate analysis, although the association lost statistical significance when the researchers adjusted for other prognostic factors such as tumor stage, tumor size and lymph node status in multivariable modeling. The authors are careful about this distinction, presenting GIRGL as a promising prognostic candidate that requires further validation in larger and more diverse patient cohorts rather than as a definitively established independent predictor.

To understand how GIRGL is switched on during metabolic crisis, the researchers traced the signaling pathway connecting glucose starvation to the GIRGL gene. Their experiments converged on a well-known cellular energy sensor: AMP-activated protein kinase, or AMPK, the molecular fuel gauge that fires when intracellular energy levels fall. Under low-glucose conditions, AMPK becomes activated, and this activation triggers the transcription factor FOXO3, prompting it to move into the cell nucleus where it can influence gene expression. Using the AMPK inhibitor dorsomorphin, the team demonstrated that blocking AMPK activity suppressed the induction of GIRGL during glucose deprivation and also interfered with the nuclear accumulation of FOXO3. In other words, the pathway runs in a clear line: energy stress activates AMPK, AMPK activates FOXO3, and FOXO3 drives the expression of GIRGL. This places GIRGL downstream of one of the most conserved stress-sensing circuits in eukaryotic biology, suggesting that the molecule functions as a deliberate, regulated component of the cancer cell’s emergency response rather than as a random byproduct of cellular chaos.

With the induction mechanism established, the next question concerned what GIRGL actually does. The researchers deployed locked nucleic acid antisense oligonucleotides, chemically modified DNA-like strands engineered to bind specifically to GIRGL and trigger its degradation, to silence the molecule in lung adenocarcinoma cell lines including A549 and NCI-H1299. The consequences were dramatic. Cells lacking GIRGL showed reduced glucose uptake, diminished lactate secretion and lower pyruvate production, the three classic readouts of aerobic glycolysis, the fermentative metabolism famously favored by cancer cells even in the presence of oxygen. Seahorse extracellular flux analysis, a technique that measures real-time oxygen consumption and acid production in living cells, confirmed that GIRGL silencing fundamentally altered the metabolic profile of the cells. Beyond metabolism, GIRGL depletion also impaired the malignant behaviors that depend on it: proliferation, migration and invasion all declined when the RNA was removed.

The pivotal downstream effector of GIRGL turned out to be MCT4, monocarboxylate transporter 4, a membrane protein responsible for exporting lactate out of the cell. In glycolytic tumors, lactate is produced in enormous quantities, and its accumulation inside the cell would acidify the cytoplasm to lethal levels without efficient export mechanisms. MCT4 serves as the primary lactate efflux pump in highly glycolytic cells, and its expression is often elevated in aggressive cancers. The new study showed that GIRGL promotes the expression of MCT4, and that this upregulation is the mechanism by which GIRGL drives metabolic reprogramming and tumor progression. When the researchers restored MCT4 in GIRGL-deficient cells, key metabolic parameters partially recovered, confirming that MCT4 is a functionally important mediator of GIRGL’s effects rather than an incidental passenger.

Mechanistically, the connection between GIRGL and MCT4 runs through a third party: the transcription factor YBX1, also known as Y-box binding protein 1. Fluorescence in situ hybridization experiments localized GIRGL within the cells, and RNA pulldown assays combined with RNA immunoprecipitation demonstrated a direct physical interaction between the GIRGL transcript and the YBX1 protein. Chromatin immunoprecipitation then showed that YBX1 binds to the promoter region of the MCT4 gene. The picture that emerges is one of molecular hand-holding: GIRGL acts as an RNA scaffold or guide that engages YBX1 and potentiates YBX1-mediated transcription of MCT4, thereby boosting the cell’s capacity to ship lactate out and sustain its glycolytic flux. Deletion mapping experiments suggested that specific regions of the GIRGL transcript mediate the interaction with YBX1, providing structural clues that could inform the design of future therapeutic molecules targeting this RNA-protein interface.

The researchers did not confine their work to laboratory dishes. To test whether GIRGL influences tumor behavior in living organisms, they employed xenograft mouse models, implanting human lung adenocarcinoma cells and tracking tumor growth. Complementing these studies, 18F-fluorodeoxyglucose micro-PET/CT imaging allowed the team to visualize glucose uptake within the implanted tumors non-invasively, bridging the cellular assays and the clinical imaging observations made in patients. The in vivo findings were consistent with the in vitro data, reinforcing the conclusion that GIRGL is not an artifact of cell culture but a genuine contributor to tumor metabolism and progression in a living system.

The broader significance of the study lies in how it reframes the role of long non-coding RNAs in cancer metabolism. Much of the classical work on the Warburg effect and glycolytic reprogramming has centered on protein-coding genes and their regulators, from HIF-1alpha to c-Myc. By identifying an energy-stress-induced lncRNA that operates through the AMPK-FOXO3 axis and partners with YBX1 to control a key metabolic transporter, the study adds a regulatory RNA layer to the established circuitry of metabolic adaptation. It also suggests that the RNA molecules induced under stress conditions are not noise but functional amplifiers of the stress response, tuned by evolution to help cells that must endure scarcity. For tumor cells, that same survival machinery becomes a weapon, enabling growth in environments that should be lethal.

Therapeutically, the findings open several avenues worth pursuing. GIRGL itself could serve as a biomarker, potentially measured in tumor biopsies to gauge the metabolic aggressiveness of a lung adenocarcinoma, though the authors emphasize that its independent prognostic value still needs confirmation through multivariable validation in larger cohorts. The GIRGL-YBX1-MCT4 axis, meanwhile, represents a cascade of potential drug targets: antisense oligonucleotide technology already exists to silence lncRNAs, inhibitors of YBX1 and of MCT4 are under active investigation in oncology, and interrupting the physical interaction between GIRGL and YBX1 offers a conceptually elegant point of attack. As with all early translational findings, the road from mechanism to medicine is long, but this study provides a clear map of a previously hidden pathway that lung cancer cells use to survive their own self-created energy crisis, and in doing so adds a compelling new chapter to the growing catalog of non-coding RNAs that shape the metabolic destiny of tumors.

Subject of Research: Energy stress-induced lncRNA GIRGL regulating glucose metabolism reprogramming via YBX1 and MCT4 in lung adenocarcinoma

Article Title: Energy stress-induced lncRNA GIRGL modulates glucose metabolism reprogramming through upregulating MCT4 by interacting with YBX1 in lung adenocarcinoma

Article References: Luo, J., Zha, W., Yao, J., Wen, Y., Huang, H., Wang, Z., Wang, G., Zhang, Y., Huang, Z., Qiang, Y., Hu, L., Shen, Y., Cong, Z., & Yao, Y. (2026). Energy stress-induced lncRNA GIRGL modulates glucose metabolism reprogramming through upregulating MCT4 by interacting with YBX1 in lung adenocarcinoma. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08977-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08977-3

Keywords: GIRGL, lung adenocarcinoma, glucose metabolism, metabolic reprogramming, long non-coding RNA, MCT4, YBX1, AMPK, FOXO3, aerobic glycolysis, lactate transport, tumor microenvironment